212 47

Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity

Title
Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity
Author
최찬범
Keywords
SYSTEMIC-LUPUS-ERYTHEMATOSUS; PSYCHOMETRIC QUALITIES; IMPORTANT DIFFERENCE; BILAG-2004 INDEX; SEVERITY INDEX; FATIGUE; INSTRUMENT; SCALE; VALIDITY; THERAPY
Issue Date
2016-01
Publisher
BIOMED CENTRAL LTD
Citation
ARTHRITIS RESEARCH & THERAPY, v. 18, Article number 1, Page. 1-5
Abstract
Since the 2002 Dusseldorf meeting, one new agent, Benlysta, has been approved by the US Food and Drug Administration for systemic lupus erythematosus. Experiences from the field in conducting trials of all the agents tested during this period have provided valuable practical insights. There has been incremental progress in defining the minimal clinically important difference (MCID) of key disease manifestations and the view is largely that of the health care providers and not that of the person suffering the disease. This basic methodological work on the MCID should improve the efficiency and the clinical relevance of future trials and their design.
URI
https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-015-0906-9http://hdl.handle.net/20.500.11754/30608
ISSN
1478-6354; 1478-6362
DOI
10.1186/s13075-015-0906-9
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE